Header Logo

Connection

SANJAY MATHEW to Male

Back to Details
This is a "connection" page, showing publications SANJAY MATHEW has written about Male.
SANJAY MATHEW
Connection Strength
0.744
Male
  1. Anti-suicidal effects of IV ketamine in a real-world setting. Psychiatry Res. 2024 Jan; 331:115604.
    View in: PubMed
    Score: 0.037
  2. Replication of distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2023 01 15; 321:140-146.
    View in: PubMed
    Score: 0.035
  3. Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression. Int J Neuropsychopharmacol. 2021 05 18; 24(5):383-391.
    View in: PubMed
    Score: 0.031
  4. ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. Contemp Clin Trials. 2019 02; 77:19-26.
    View in: PubMed
    Score: 0.026
  5. Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression. J Affect Disord. 2018 12 01; 241:514-518.
    View in: PubMed
    Score: 0.026
  6. Neurobiology of the dorsolateral prefrontal cortex in GAD: Aberrant neurometabolic correlation to hippocampus and relationship to anxiety sensitivity and IQ. J Affect Disord. 2018 03 15; 229:1-13.
    View in: PubMed
    Score: 0.025
  7. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology. 2017 Dec; 42(13):2567-2574.
    View in: PubMed
    Score: 0.024
  8. Impact of childhood emotional abuse on neocortical neurometabolites and complex emotional processing in patients with generalized anxiety disorder. J Affect Disord. 2016 Jan 15; 190:414-423.
    View in: PubMed
    Score: 0.021
  9. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014 Apr; 31(4):335-43.
    View in: PubMed
    Score: 0.019
  10. Reduced hippocampal N-acetyl-aspartate (NAA) as a biomarker for overweight. Neuroimage Clin. 2014; 4:326-35.
    View in: PubMed
    Score: 0.019
  11. Glycine transporter-I inhibitors: a new class of antidepressant? Biol Psychiatry. 2013 Nov 15; 74(10):710-1.
    View in: PubMed
    Score: 0.019
  12. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013 Oct; 170(10):1134-42.
    View in: PubMed
    Score: 0.018
  13. Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR Biomed. 2012 Sep; 25(9):1073-87.
    View in: PubMed
    Score: 0.016
  14. A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol. 2011 Mar; 21(3):221-9.
    View in: PubMed
    Score: 0.015
  15. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010 Jan 15; 67(2):139-45.
    View in: PubMed
    Score: 0.014
  16. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009 Sep 01; 66(5):522-6.
    View in: PubMed
    Score: 0.014
  17. Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T (1)H MRS imaging study. NMR Biomed. 2009 Apr; 22(3):251-8.
    View in: PubMed
    Score: 0.014
  18. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010 Feb; 13(1):71-82.
    View in: PubMed
    Score: 0.013
  19. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry. 2009 May 01; 65(9):792-800.
    View in: PubMed
    Score: 0.013
  20. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study. Clin Ther. 2008 Sep; 30(9):1658-66.
    View in: PubMed
    Score: 0.013
  21. Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biol Psychiatry. 2008 May 01; 63(9):891-8.
    View in: PubMed
    Score: 0.012
  22. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry. 2005 Dec; 162(12):2379-81.
    View in: PubMed
    Score: 0.011
  23. Aperiodic (1/f) Neural Activity Robustly Tracks Symptom Severity Changes in Treatment-Resistant Depression. Biol Psychiatry Cogn Neurosci Neuroimaging. 2025 Feb; 10(2):186-194.
    View in: PubMed
    Score: 0.010
  24. Beta activity in human anterior cingulate cortex mediates reward biases. Nat Commun. 2024 Jul 15; 15(1):5528.
    View in: PubMed
    Score: 0.010
  25. Cost-effectiveness and threshold analysis of deep brain stimulation vs. treatment-as-usual for treatment-resistant depression. Transl Psychiatry. 2024 Jun 07; 14(1):243.
    View in: PubMed
    Score: 0.010
  26. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 06 03; 7(6):e2417786.
    View in: PubMed
    Score: 0.010
  27. Dorsolateral prefrontal cortical pathology in generalized anxiety disorder: a proton magnetic resonance spectroscopic imaging study. Am J Psychiatry. 2004 Jun; 161(6):1119-21.
    View in: PubMed
    Score: 0.010
  28. Improved implicit self-esteem is associated with extended antidepressant effects following a novel synergistic intervention. Mol Psychiatry. 2024 Nov; 29(11):3431-3439.
    View in: PubMed
    Score: 0.010
  29. Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. Mol Psychiatry. 2024 Aug; 29(8):2287-2295.
    View in: PubMed
    Score: 0.010
  30. Neural connectivity moderators and mechanisms of ketamine treatment among treatment-resistant depressed patients: a?randomized controlled trial. EBioMedicine. 2024 Jan; 99:104902.
    View in: PubMed
    Score: 0.009
  31. A magnetic resonance spectroscopic imaging study of adult nonhuman primates exposed to early-life stressors. Biol Psychiatry. 2003 Oct 01; 54(7):727-35.
    View in: PubMed
    Score: 0.009
  32. Cerebrospinal fluid concentrations of biogenic amines and corticotropin-releasing factor in adolescent non-human primates as a function of the timing of adverse early rearing. Stress. 2002 Sep; 5(3):185-93.
    View in: PubMed
    Score: 0.009
  33. Nighttime Sleep Quality and Daytime Sleepiness Predicts Suicide Risk in Adults Admitted to an Inpatient Psychiatric Hospital. Behav Sleep Med. 2023 Mar-Apr; 21(2):129-141.
    View in: PubMed
    Score: 0.008
  34. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset. J Clin Psychiatry. 2021 06 15; 82(4).
    View in: PubMed
    Score: 0.008
  35. Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. Am J Psychiatry. 2021 05 01; 178(5):437-446.
    View in: PubMed
    Score: 0.008
  36. Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. J Clin Psychopharmacol. 2020 May/Jun; 40(3):287-292.
    View in: PubMed
    Score: 0.007
  37. A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating ?-opioid antagonism as a treatment for anhedonia. Nat Med. 2020 05; 26(5):760-768.
    View in: PubMed
    Score: 0.007
  38. Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. J Affect Disord. 2020 01 01; 260:131-139.
    View in: PubMed
    Score: 0.007
  39. Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. J Affect Disord. 2019 11 01; 258:102-108.
    View in: PubMed
    Score: 0.007
  40. A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. Am J Psychiatry. 2019 11 01; 176(11):923-930.
    View in: PubMed
    Score: 0.007
  41. Trajectories of self-reported sleep disturbance across inpatient psychiatric treatment predict clinical outcome in comorbid major depressive disorder and generalized anxiety disorder. J Affect Disord. 2019 05 15; 251:248-255.
    View in: PubMed
    Score: 0.007
  42. Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology. 2019 06; 44(7):1233-1238.
    View in: PubMed
    Score: 0.007
  43. Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. J Psychiatr Res. 2019 03; 110:166-171.
    View in: PubMed
    Score: 0.007
  44. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019 03; 36(3):235-243.
    View in: PubMed
    Score: 0.007
  45. Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. Transl Psychiatry. 2018 12 14; 8(1):280.
    View in: PubMed
    Score: 0.007
  46. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020 07; 25(7):1592-1603.
    View in: PubMed
    Score: 0.007
  47. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry. 2018 02 01; 175(2):150-158.
    View in: PubMed
    Score: 0.006
  48. The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder. Neuropsychopharmacology. 2017 Jul; 42(8):1739-1746.
    View in: PubMed
    Score: 0.006
  49. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Neuropsychopharmacology. 2017 Mar; 42(4):844-853.
    View in: PubMed
    Score: 0.006
  50. Heightened early-attentional stimulus orienting and impulsive action in men with antisocial personality disorder. Eur Arch Psychiatry Clin Neurosci. 2017 Oct; 267(7):697-707.
    View in: PubMed
    Score: 0.006
  51. Operationalizing NIMH Research Domain Criteria (RDoC) in naturalistic clinical settings. Bull Menninger Clin. 2016; 80(3):187-212.
    View in: PubMed
    Score: 0.005
  52. Patterns of anterior versus posterior white matter fractional anistotropy concordance in adult nonhuman primates: Effects of early life stress. J Affect Disord. 2016 Mar 01; 192:167-75.
    View in: PubMed
    Score: 0.005
  53. Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies. J Clin Psychopharmacol. 2015 Aug; 35(4):454-9.
    View in: PubMed
    Score: 0.005
  54. Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder. Eur Neuropsychopharmacol. 2015 Aug; 25(8):1082-90.
    View in: PubMed
    Score: 0.005
  55. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology. 2015 Mar 13; 40(5):1084-90.
    View in: PubMed
    Score: 0.005
  56. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015 Mar; 76(3):247-52.
    View in: PubMed
    Score: 0.005
  57. A Novel Anxiety and Affective Spectrum Disorder of Mind and Body-The ALPIM (Anxiety-Laxity-Pain-Immune-Mood) Syndrome: A Preliminary Report. J Neuropsychiatry Clin Neurosci. 2015; 27(2):93-103.
    View in: PubMed
    Score: 0.005
  58. Hippocampal volume and the rapid antidepressant effect of ketamine. J Psychopharmacol. 2015 May; 29(5):591-5.
    View in: PubMed
    Score: 0.005
  59. In vivo (1)H MRS study of potential associations between glutathione, oxidative stress and anhedonia in major depressive disorder. Neurosci Lett. 2014 May 21; 569:74-9.
    View in: PubMed
    Score: 0.005
  60. Riluzole effect on occipital cortex: a structural and spectroscopy pilot study. Neurosci Lett. 2012 Nov 14; 530(1):103-7.
    View in: PubMed
    Score: 0.004
  61. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013 Aug 15; 74(4):250-6.
    View in: PubMed
    Score: 0.004
  62. A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD. Eur Neuropsychopharmacol. 2013 Apr; 23(4):276-84.
    View in: PubMed
    Score: 0.004
  63. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. Bipolar Disord. 2012 Feb; 14(1):64-70.
    View in: PubMed
    Score: 0.004
  64. Metabolic syndrome and neurometabolic asymmetry of hippocampus in adult bonnet monkeys. Physiol Behav. 2011 Jul 06; 103(5):535-9.
    View in: PubMed
    Score: 0.004
  65. Tryptophan depletion and emotional processing in healthy volunteers at high risk for depression. Biol Psychiatry. 2011 Apr 15; 69(8):804-7.
    View in: PubMed
    Score: 0.004
  66. Early-life stress, corpus callosum development, hippocampal volumetrics, and anxious behavior in male nonhuman primates. Psychiatry Res. 2011 Apr 30; 192(1):37-44.
    View in: PubMed
    Score: 0.004
  67. Early-life stress and neurometabolites of the hippocampus. Brain Res. 2010 Oct 28; 1358:191-9.
    View in: PubMed
    Score: 0.004
  68. The role of early life stress in development of the anterior limb of the internal capsule in nonhuman primates. Neurosci Lett. 2010 Aug 16; 480(2):93-6.
    View in: PubMed
    Score: 0.004
  69. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2008 Apr; 28(2):235-9.
    View in: PubMed
    Score: 0.003
  70. Maternal-infant response to variable foraging demand in nonhuman primates: effects of timing of stressor on cerebrospinal fluid corticotropin-releasing factor and circulating glucocorticoid concentrations. Ann N Y Acad Sci. 2006 Jul; 1071:525-33.
    View in: PubMed
    Score: 0.003
  71. Twenty-four-hour cortisol secretion patterns in prepubertal children with anxiety or depressive disorders. Biol Psychiatry. 2004 Aug 01; 56(3):198-204.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.